MA44972A - Procédés d'identification de modulateurs du cftr - Google Patents

Procédés d'identification de modulateurs du cftr

Info

Publication number
MA44972A
MA44972A MA044972A MA44972A MA44972A MA 44972 A MA44972 A MA 44972A MA 044972 A MA044972 A MA 044972A MA 44972 A MA44972 A MA 44972A MA 44972 A MA44972 A MA 44972A
Authority
MA
Morocco
Prior art keywords
identification processes
cftr modulator
modulator identification
cftr
processes
Prior art date
Application number
MA044972A
Other languages
English (en)
Inventor
Lawrence J Ii Drew
Po-Shun Lee
John Miller
Original Assignee
Proteostasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proteostasis Therapeutics Inc filed Critical Proteostasis Therapeutics Inc
Publication of MA44972A publication Critical patent/MA44972A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics
    • G01N2800/382—Cystic fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
MA044972A 2016-05-09 2017-05-09 Procédés d'identification de modulateurs du cftr MA44972A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662333537P 2016-05-09 2016-05-09

Publications (1)

Publication Number Publication Date
MA44972A true MA44972A (fr) 2019-03-20

Family

ID=58739383

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044972A MA44972A (fr) 2016-05-09 2017-05-09 Procédés d'identification de modulateurs du cftr

Country Status (6)

Country Link
US (1) US20190154661A1 (fr)
EP (1) EP3455624A1 (fr)
AU (1) AU2017264612A1 (fr)
CA (1) CA3023512A1 (fr)
MA (1) MA44972A (fr)
WO (1) WO2017196843A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10047051B2 (en) * 2015-06-02 2018-08-14 Abbvie S.Á.R.L. Substituted pyridines and method of use
US10548878B2 (en) 2015-07-24 2020-02-04 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods of increasing CFTR activity
SG11201802798WA (en) 2015-10-06 2018-05-30 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr
WO2017177124A1 (fr) 2016-04-07 2017-10-12 Proteostasis Therapeutics, Inc. Atomes de silicone contenant des analogues d'ivacaftor
ES2954658T3 (es) 2016-06-21 2023-11-23 Proteostasis Therapeutics Inc Compuestos, composiciones y procedimientos para aumentar la actividad de CFTR
WO2020006269A1 (fr) 2018-06-27 2020-01-02 Proteostasis Therapeutics, Inc. Composés améliorant l'activité du protéasome
US20200383960A1 (en) * 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010088630A2 (fr) * 2009-02-02 2010-08-05 Chromocell Corporation Lignées cellulaires exprimant cftr et procédés d'utilisation associés
CN104478882A (zh) * 2010-09-14 2015-04-01 波兰科学院生物化学与生物物理研究所 作为突变cftr蛋白的调节剂的化合物及其在治疗与cftr蛋白失常相关的疾病中的用途
AU2014302458A1 (en) 2013-06-26 2015-12-24 Proteostasis Therapeutics, Inc. Methods of modulating CFTR activity
CA2942386A1 (fr) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Composes, compositions et procedes pour augmenter l'activite du cftr
AU2015229117A1 (en) 2014-03-13 2016-09-29 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing CFTR activity
EP3157917B1 (fr) 2014-06-19 2020-03-18 Proteostasis Therapeutics, Inc. Composés, compositions et procédés pour augmenter l'activité du cftr
SG11201802798WA (en) 2015-10-06 2018-05-30 Proteostasis Therapeutics Inc Compounds, compositions, and methods for modulating cftr

Also Published As

Publication number Publication date
CA3023512A1 (fr) 2017-11-16
EP3455624A1 (fr) 2019-03-20
US20190154661A1 (en) 2019-05-23
AU2017264612A1 (en) 2018-11-22
WO2017196843A1 (fr) 2017-11-16

Similar Documents

Publication Publication Date Title
EP3468725C0 (fr) Appareil de revêtement de tuyaux
EP3436581A4 (fr) Procédés d'amplification de transcriptome entier
MA55748A (fr) Procédés de détection d'aav
EP3430731A4 (fr) Architecture d'iugw
EP3485773A4 (fr) Buse d'aspirateur
EP3478229A4 (fr) Dispositif d'ouverture optimale des voies respiratoires.
EP3387023A4 (fr) Procédés de récupération d'hydrocarbure
EP3507335A4 (fr) Revêtements polymères
PL3311169T3 (pl) Oznaczenie do identyfikacji modulatorów
EP3439412A4 (fr) Procédés de configuration et d'envoi de préambule, et dispositifs associés
EP3474165A4 (fr) Système de conception d'assistance
EP3443293A4 (fr) Capteurs d'effort
EP3558312A4 (fr) Procédés d'amélioration de la densité vasculaire
MA41296A (fr) Procédés de transdifférenciation et procédés d'utilisation de ceux-ci
EP3371730A4 (fr) Évaluation automatisée de la qualité d'un échantillon
EP3556455A4 (fr) Appareil de production d'urée
MA41298A (fr) Procédés de marquage de banques codées par de l'adn
EP3433383A4 (fr) Procédés d'amplification quantitative
EP3512403A4 (fr) Système d'inspection d'orifice
EP3606757C0 (fr) Appareil de dépôt par pulvérisation
EP3429690A4 (fr) Procédés pour moduler keap1
EP3535061A4 (fr) Buse microstructurée
EP3257417C0 (fr) Buse d'aspirateur
EP3431808A4 (fr) Butée d'arrêt
DK3343570T3 (da) 68GE/68GA-generator